Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 2.29 and has seen 1.02 million shares traded in the last trading session. The company, currently valued at $256.95M, closed the last trade at $3.98 per share which meant it gained $0.01 on the day or 0.13% during that session. The INZY stock price is -56.78% off its 52-week high price of $6.24 and 81.91% above the 52-week low of $0.72.
The consensus among analysts is that Inozyme Pharma Inc (INZY) is Buy stock at the moment, with a recommendation rating of 2.75. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Sporting 0.13% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the INZY stock price touched $3.98 or saw a rise of 0.25%. Year-to-date, Inozyme Pharma Inc shares have moved 43.68%, while the 5-day performance has seen it change 0.63%. Over the past 30 days, the shares of Inozyme Pharma Inc (NASDAQ:INZY) have changed 145.68%.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 0.5% from current levels. The projected low price target is $4.0 while the price target rests at a high of $4.0. In that case, then, we find that the current price level is -0.5% off the targeted high while a plunge would see the stock gain -0.5% from current levels.
Inozyme Pharma Inc (INZY) estimates and forecasts
The company’s shares have gained 46.32% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.98% over the past 5 years. Earnings growth for 2025 is a modest 11.66% while over the next 5 years, the company’s earnings are expected to increase by 21.72%.
INZY Dividends
Inozyme Pharma Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
The top two institutional holders are ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares worth more than $25.55 million. As of 2024-06-30, ADAGE CAPITAL PARTNERS GP, L.L.C. held 9.2484% of shares outstanding.
The other major institutional holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with the holding of over 4.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $20.05 million and represent 7.2563% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 2.61% shares in the company for having 1.69 shares of worth $6.72 million while later fund manager owns 1.37 shares of worth $5.45 million as of Mar 31, 2025 , which makes it owner of about 2.12% of company’s outstanding stock.
